Clear Cell Adenocarcinoma — Trials

Clear Cell Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 150
Recruiting: 79
Ph III recruiting: 9
Growth YoY: −15.8%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 51–60 of 60 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01141569	A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy	completed	Phase 2	12	National Cancer Institute (NCI)NIH	1	Mar 10, 2017	clinicaltrials
NCT02607553	Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA	completed	Phase 2	2	GenSpera, Inc.INDUSTRY	1	Feb 24, 2017